Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
RLY-8161 in NRAS Mutant Melanoma: NCT07584226 Clinical Landscape Report 2026
16 September 2026
NCT07584226 clinical landscape for NRAS Mutant Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CS08399 in Locally Advanced Malignant Solid Neoplasm: NCT07583771 Clinical Landscape Report 2026
16 September 2026
NCT07583771 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
SENL-103 in Multiple Sclerosis, Primary Progressive: NCT07587125 Clinical Landscape Report 2026
16 September 2026
NCT07587125 clinical landscape for Multiple Sclerosis, Primary Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
LVIVO-TaVec400 in Myasthenia Gravis: NCT07583030 Clinical Landscape Report 2026
16 September 2026
NCT07583030 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cadonilimab in Melanoma, Cutaneous Malignant: NCT07586904 Clinical Landscape Report 2026
16 September 2026
NCT07586904 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Universal allogeneic anti-CD19/BCMA CAR T-cells(The Children's Hospital of Zhejiang University School of Medicine) in Granulomatosis With Polyangiitis: NCT07586267 Clinical Landscape Report 2026
16 September 2026
NCT07586267 clinical landscape for Granulomatosis With Polyangiitis: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
REGN4336 in Renal Cell Carcinoma: NCT07594106 Clinical Landscape Report 2026
16 September 2026
NCT07594106 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MTM-H-001 in Myasthenia Gravis: NCT07593911 Clinical Landscape Report 2026
16 September 2026
NCT07593911 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Beta-Hydroxy-Beta-Methylbutyrate in Amyotrophic Lateral Sclerosis: NCT07589764 Clinical Landscape Report 2026
16 September 2026
NCT07589764 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
p95HER2.CAR-TECH2Me T cells (Vall d'Hebron Institut d'Oncologia) in Metastatic endometrial cancer: NCT07593820 Clinical Landscape Report 2026
16 September 2026
NCT07593820 clinical landscape for Metastatic endometrial cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HW241045 in Idiopathic Pulmonary Fibrosis: NCT07593690 Clinical Landscape Report 2026
16 September 2026
NCT07593690 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bendamustine Hydrochloride in High grade B-cell lymphoma: NCT07593482 Clinical Landscape Report 2026
16 September 2026
NCT07593482 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.